


SYNTHESIS OF ETOPOSIDE LACTAM
VIA A MITSUNOBU REACTION SEQUENCE

J.F.Kadow*, D.M.Vyas, and T.W.Doyle

Bristol-Myers Company, Pharmaceutical Research and Development Division,
5-Research Parkway, P.O. Box 5100
Wallingford, Connecticut, 06492-7660

Abstract: A novel chemical sequence for the conversion of a lactone antitumor agent 1 (etoposide) to the corresponding lactam 2 is described. The key steps involve a Mitsunobu cyclization (Ph_3P , DEAD) of the γ -hydroxymethyl acyl benzaldehyde hydrazone 6 to a lactam derivative 7 followed by reductive cleavage (Ra-Ni) to lactam 2.

Etoposide (1) is an antitumor agent which is currently in clinical use for the treatment of testicular cancer and small cell lung cancer.¹ Metabolism studies have shown that *in-vivo* the strained *trans* lactone of 1 can be hydrolyzed and epimerized to the corresponding hydroxyacid and *cis* lactone;² derivatives which display greatly diminished biological activity. Other D ring analogs have therefore been synthesized in an attempt to provide resistance to such deactivating processes.³



1, X=O, ETOPOSIDE


2, X=NH

In this communication, we report a mild approach to convert the readily epimerizable, *trans* lactone moiety present in the highly functionalized compound 1, to a *trans* lactam via a sequence of reactions which should find utility in organic synthesis. We felt the lactam analog 2 would be resistant to hydrolysis and epimerization while hopefully retaining the antitumor activity of 1.

Our initial attempts to directly convert the lactone moiety of 1 to a lactam using NH_3 and heat were unsuccessful.⁴ Ring opening of 1 with either LiH or ammonia was never useful in our hands. However reaction with hydrazine in refluxing MeOH/AcOH provided a mixture of the desired *trans* hydrazide 3 (50%) along with nearly equivalent amounts of the epimerized *cis* hydrazide 4 (40%) (Scheme 1).⁵ Although the two hydrazides appeared quite

amenable to chromatographic separation, *cis* hydrazide **4** was, fortuitously, essentially insoluble in the reaction medium and could be easily removed by filtration.⁶ The *trans* stereochemistry of the desired hydrazide **3** was confirmed by reacting the compound with 1.1 eq. NaNO_2 in THF/AcOH to regenerate **1** in nearly quantitative yield (Scheme 1).⁷

SCHEME 1



R= β -D-4,6-O-ethylidene glucose. Ar= 3,5-dimethoxy-4-hydroxy phenyl

a) NH_2NH_2 , AcOH, MeOH, reflux, 2h (see ref. 6). b) 1.1eq. NaNO_2 , THF, AcOH, 2° to 25° 16h. c) Raney Nickel (W-2), EtOH, reflux. d) see text.


Our efforts to convert *trans* hydrazide **3** directly to a cyclized lactam were unsuccessful and limited by the compound's poor solubility. The corresponding *trans* amide **5** or fully protected counterparts also failed to provide a lactam using a variety of strategies.⁸ The direct Mitsunobu reactions on either hydrazide **3** or amide **5** failed to provide the desired cyclized products.⁹

However, the earlier report of the cyclization of β -hydroxy hydroxamates used by Miller and coworkers¹⁰ for the synthesis of β -lactam intermediates suggested that protection of the hydrazide moiety in **3** would facilitate a Mitsunobu cyclization. [To our knowledge, the preparation of five membered ring lactams via such a cyclization has not been reported.] A suspension of **3** was reacted with excess benzaldehyde in 4:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ at 25° to provide the *trans* hydroxymethyl acyl benzaldehyde hydrazone **6** in 87% yield (Scheme 2). Addition of DEAD (1.8 eq) to a THF solution (22mL/mmol substrate) of Ph_3P (3 eq) and **6** followed by stirring for 20 min at 25° provided the desired cyclized product **7** in 90% yield after aqueous workup and flash chromatographic purification. Traces of products resulting from O-cyclization could only occasionally be detected in the crude product in contrast to ketone hydrazones or amidine analogs of hydrazide **3**.^{11,12}

Epimerization of **7** (KOtBu, DMF, 70°) provided the more stable *cis* substituted lactam **8** thereby confirming the stereochemical assignment of the cyclization product. Synthesis

of **8** from the *cis* hydrazone **4** using the same sequence described above for the corresponding *trans* hydrazone proceeds without complication in similar overall yield.

SCHEME 2



R=β-D-4,6-O-ethylidene glucose. Ar= 3,5-dimethoxy-4-hydroxy phenyl.

a) excess PhCHO, 4:1 CH₂Cl₂, 25°. b) 1.8eq. DEAD, 3eq. PPh₃, THF, 25°, 20min.

c) Raney Nickel (W-2), EtOH reflux.


Reduction of **7** in ethanol at reflux for 6 h with an excess of Raney Nickel (Aldrich, W-2), which had been previously washed with water [until the washes were no longer basic], provided a 68% yield of the target lactam analog **2** and 14% of the incompletely reduced benzyl hydrazide **10** after flash chromatography (eq.3). However, hydrogenation of **7** with 10% Pd/C in ethanol at 25° for 3h provides benzyl hydrazide **9** in 55% yield without further reduction. Subjecting **8** to the same Raney-Nickel reduction used above for **7**, produces the corresponding *cis* lactam.

To summarize, using the sequence described above (hydrazine ring opening, Schiff base formation, cyclization, and N-N bond cleavage) the lactone moiety of etoposide has been efficiently converted to a lactam ring. Both *cis* and *trans* fused γ-lactam rings were formed with equal effectiveness from γ-hydroxymethyl acyl benzaldehyde hydrazones under Mitsunobu conditions. Work to define the generality of this sequence on unrelated substrates and the scope of this cyclization procedure is in progress. The biological activity of the compounds described herein will be reported elsewhere.

REFERENCES

- Issel, B.F.; Muggia, F.M.; Carter, S.K. "Etoposide (VP-16): Current Status and New Developments" Academic Press, Inc., New York, 1984.
- a) Hande, K.; Anthony, L.; Hamilton, R.; Bennet, R.; Sweetman, B.; Branch, R. **Cancer Research** 1988, **48**, 1829. b) Creaven, P.J., **Cancer Chemother. Pharmacol.**, 1982, **7**, 133. c) Evans, W.E., Sinkule, J.A., Crom, W.R., Dow, L.; Rivera, G. **Ibid.**, 1982, **7**,

147. d) Ref. 3b and references therein.
3. a) Gensler, W.J.; Murthy, C.D.; Trammel, M.H. *J. Med. Chem.* 1977, **20**, 635. b) Jardine, I.; Strife, R.J.; Kozlowski, J. *Ibid.* 1982, **25**, 1077. c) Pearce, H.L.; Bach, N.J.; Cramer, T.L. *Tetrahedron Lett.* 1989, **30**, 907.
 4. Anjanamurthyl, C.; Lokanatha Rai, K.M. *Ind. J. Chem.*, 1987, **26B**, 131.
 5. Ring opening of a similar lignan aglycone has been reported to occur without epimerization: a) Rutschmann, J.; Renz, J. *Helv. Chim. Acta.* 1959, **42**, 890-907. b) Rutschmann, J. U.S. 2,984,674; May 16, 1961.
 6. The reaction is run using the following quantities of reagent: 10g of etoposide, 100 mL of Methanol, 10 mL of hydrazine, and 10 mL of glacial acetic acid. The cis and trans hydrazides are distinct by TLC on SiO₂ using 10%MeOH/CH₂Cl₂ as eluent.
 7. All new compounds have been fully characterized spectroscopically and by elemental analysis. High field ¹H and ¹³C NMR spectra of lactam analogs corresponded well to those of the lactone series.
 8. For example: heat or [TsCl, Pyr] or [SOCl₂/Pyr] or [Ph₃P, CCl₄] or [i) PPh₃, DEAD, (PhO)₂PON₃, ii) azide reduction and cyclization]. Fully or partially silyated 5 as well as carbonate derivatives were also explored without success.
 9. For a review of the use of DEAD/PPh₃ see: Mitsunobu, O. *Synthesis* 1981, 1.
 10. Miller, M.J. *Acc. Chem. Res.* 1986, **19**, 49; and references therein.
 11. The conditions for this reaction have been determined empirically and have not been exhaustively explored. When aldehydes were used to form the Schiff bases, only traces of products tentatively identified as arising from O-cyclization have been detected. However preliminary results using ketone Schiff bases or N,N-dialkyl amidines similar to 6 have shown that appreciable amounts of stable O-cyclization products 10 may be isolated.



10

12. Since the completion of this work the synthesis of β -lactams via Mitsunobu cyclization of β -hydroxy acyl benzophenone hydrazones has been reported: Curran, W.V.; Ross, A.A; Lee, V.J. *J. of Antibiotics* 1988, **XLI**, 1419.

(Received in USA 5 April 1989)